Search Bar & Filters
Found 20 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting a long-term extension study to evaluate the safety, tolerability, and effectiveness of ORX750 in adults aged 18 to 65 years who have narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia. This study follows participants who completed a previous ORX750 clinical trial and focuses on providing ongoing information about the treatment over an extended period. Participants will receive oral ORX750 in an open-label format, grouped by their specific diagnosis narcolepsy type 1, narcolepsy type 2, or idiopathic hypersomnia. The study does not involve randomization or blinding, allowing all participants to know they are receiving the study drug. The treatment and monitoring periods include assessments up to about 70 days for safety and roughly 63 days for measures of drug concentration and wakefulness. During the study, participants will undergo frequent evaluations including monitoring for adverse events, laboratory tests, vital signs, ECGs, and assessments for suicidal thoughts or behaviors. They will also complete tests measuring wakefulness and sleepiness levels. This ongoing observation aims to ensure the treatments safety and to understand its effects over time, with participant involvement lasting through the entire study period.
Actively Recruiting
Researchers are studying the safety and effectiveness of NEU-411 in people aged 40 to 80 years with early Parkinsons Disease PD who have a specific genetic profile that predicts increased activity in the LRRK2 pathway. This Phase 2 study uses a companion diagnostic genetic test to identify participants with LRRK2-driven PD. The trial aims to compare NEU-411, a brain-penetrant drug that inhibits LRRK2 activity, to a placebo. Participants will be randomly assigned to receive either NEU-411 30 mg once daily or a matching placebo for 52 weeks. After this double-blind treatment period, there will be a safety follow-up visit within two weeks. Those who qualify may continue into an open-label extension phase where they will receive NEU-411 for an additional 26 weeks. Throughout the study, participants will have their Parkinsons symptoms and safety monitored using digital biomarker scores and clinical rating scales. Researchers will assess changes from baseline in the Roche digital biomarker score and the Unified Parkinsons Disease Rating Scale over the 52-week treatment period. Safety will be tracked by recording adverse events through the end of the study. Total participation may last up to 78 weeks including the extension and follow-up.
Actively Recruiting
Researchers are evaluating how efgartigimod affects thyroid function in adults with Graves Disease GD, focusing on its safety, tolerability, and impact on antibody levels and immune response. This Phase 3 study compares efgartigimod with placebo in adults whose GD is not adequately controlled with antithyroid drugs, aiming to better understand its effects on thyroid hormone levels and disease control. Participants will be randomly assigned to receive either efgartigimod PH20 subcutaneous injections via prefilled syringe or placebo during the initial double-blinded treatment period part A and treatmentobservation period part B. Those who respond may continue to an open-label treatmentobservation phase part C receiving efgartigimod. Treatment and observation durations vary, with total participation lasting from approximately 63 to 135 weeks depending on individual response. During the study, participants will undergo regular assessments of thyroid hormone levels fT3, fT4, TSH, antibody levels, and immune responses to evaluate treatment effects. Safety and tolerability will be closely monitored, and researchers will track changes in thyroid-related symptoms and quality of life. The main outcome is the percentage of participants achieving normal thyroid hormone levels without antithyroid drugs by week 24. Participants will be followed for up to nearly three years to observe long-term effects and safety.
Actively Recruiting
Researchers are evaluating the optimal doses of the drug E2086 compared to placebo in adults with narcolepsy, a condition characterized by excessive daytime sleepiness EDS. The study focuses on reducing EDS as measured by the Mean Sleep Latency MSL using the first four maintenance of wakefulness tests MWTs. This Phase 2 trial includes participants diagnosed with either narcolepsy type 1 NT1 or type 2 NT2 within the last 10 years. Participants will be randomly assigned to receive either E2086 or a matching placebo tablet taken orally once daily for four weeks at low, middle, and high doses. Each dosing period is separated by a washout period of at least seven days, with a total treatment duration of approximately 14 weeks. This design allows comparison of the effects of different doses of E2086 on narcolepsy symptoms. During the study, participants will undergo assessments to measure changes in sleep latency, cataplexy episodes, and sleepiness scales. Additional safety evaluations include monitoring for adverse events, laboratory tests, vital signs, ECG parameters, and suicidality assessments. Blood samples will be collected to analyze drug concentration levels. The study involves regular monitoring up to Day 113 and aims to assess both efficacy and safety over the course of treatment and follow-up.
Actively Recruiting
Researchers are investigating the safety, feasibility, and preliminary effectiveness of expanded allogeneic mesenchymal stem cells derived from adipose tissue HC106 for treating urinary incontinence in women over 50 years old. This phase I controlled trial aims to compare the effects of HC106 cells with a placebo in women diagnosed with stress or mixed urinary incontinence who have not responded to or declined rehabilitative or surgical treatments. Participants are divided into two groups one receives a single dose of 40 million HC016 cells injected near the external urinary sphincter, and the other receives a placebo consisting of the saline solution used to condition the cells. The injection procedure involves anesthesia, identifying the target area via cystoscopy, and carefully injecting the cell suspension at two specific points. The placebo group undergoes the same procedure using saline solution. The study uses a randomized, double-blind design. Throughout the study, participants are monitored for complications within 7 days after treatment and assessed for urinary leakage, flowmetry, and quality of life at 3 and 6 months using standardized tests and questionnaires. Researchers track safety, treatment effects, and quality of life changes over time. The total duration of participation includes initial treatment and follow-up visits up to six months.
Actively Recruiting
Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.
Actively Recruiting
This research aims to compare two surgical techniques, anterior and posterior white line advancement, for correcting primary aponeurotic ptosis in adults. The study seeks to determine if the anterior approach improves eyelid position, measured by Marginal Reflex Distance 1 MRD1, better at 6 months than the posterior approach. It also evaluates differences in eyelid symmetry, contour, vision, and patient satisfaction between the two methods. Participants will be randomly assigned to one of two groups one receiving the anterior approach involving a skin crease incision to access and advance the levator aponeurosis, and the other receiving the posterior approach, which uses a conjunctival incision without a skin cut. Both surgeries involve advancing the white line to the anterior tarsus using sutures. The study includes follow-up visits at 7 days, 2 months, and 6 months after surgery. During these visits, researchers will measure eyelid position and symmetry, evaluate eyelid contour using both software and masked evaluators, and test vision and tear film stability. Patients will also complete surveys on dry eye symptoms, scar quality, satisfaction, and psychosocial function. Surgical time and complications will be monitored. All images and data will be securely stored, and outcome assessors will be blinded to the group assignments for certain evaluations.
Actively Recruiting
Researchers are studying the use of ribociclib, a CDK46 inhibitor, in women with early hormone receptor-positive HR and HER2-negative breast cancer who are at intermediate risk of cancer recurrence. The study aims to see if patients can avoid chemotherapy, which has significant side effects, by using ribociclib along with hormone therapy after surgery. This phase III trial builds on the NATALEE study, which showed that ribociclib added to hormone therapy improved survival free of invasive disease in similar patients. Participants will be randomly assigned to one of two groups one receiving ribociclib plus endocrine hormone therapy, and the other receiving chemotherapy followed by ribociclib and endocrine therapy. Ribociclib treatment lasts for three years, and chemotherapy is given before starting ribociclib and hormone treatment. The trial aims to compare the outcomes of chemotherapy de-escalation versus standard treatment in this patient group. During the study, participants will attend scheduled visits for treatment and monitoring, including laboratory tests, heart monitoring with ECG, and questionnaires about their quality of life. Researchers will track invasive breast cancer-free survival and other outcomes such as overall survival and treatment side effects for up to 12 years. Safety and quality of life assessments will continue during and after treatment to evaluate the long-term effects and benefits of the treatment approaches.
Actively Recruiting
Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness of a remote monitoring software called Caaring in cancer patients undergoing outpatient oral cancer treatment. The study aims to see if using this self-management platform helps patients manage their illness better and reduces the number of in-person and telephone visits with specialized medical and nursing staff. This is a randomized, multicenter clinical trial comparing two groups of patients over 12 weeks. One group will use the Caaring app on their smartphones to report data and complete questionnaires related to their treatment and health. This group will also receive educational and prevention recommendations about cancer. The other group will receive routine medical follow-up visits without the remote monitoring app. Both groups will be observed for 12 weeks following their inclusion in the study. Participants will be monitored through the app or routine visits, with researchers collecting information on treatment adherence, completion of data, use of health resources, and patient satisfaction with the software. The main outcome is the percentage of adherence to prescribed treatment over 12 weeks. Secondary outcomes include data completion rates, changes in health resource use, and patient satisfaction. The study involves regular assessments and questionnaires, with a total participation duration of 12 weeks.
1-10 of 20
1